Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048059 · ClinicalTrials.gov registry record · Phase 2
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase 2 study of Breast Cancer and Brain Metastases, sponsored by Angiochem.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 19
- Study locations
NCT02048059: Completed Phase 2 study of Breast Cancer and Brain Metastases, sponsored by Angiochem.
NCT02048059 is a Phase 2 study of Breast Cancer and Brain Metastases that has completed, run by Angiochem. The registered enrollment target is 72 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 19 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02048059, a Phase 2 study of Breast Cancer and Brain Metastases, has completed, sponsored by Angiochem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
Conditions Studied
Interventions
- DRUG ANG1005
Study Locations (19)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California - LAC Medical Center - Los Angeles
- University of Southern California - Norris Comprehensive Cancer Center - Los Angeles
- UC - Irvine Chao Family Comprehensive Cancer Center - Orange
Maryland
- University of Maryland - Greenebaum Cancer Center - Baltimore
- National Cancer Institute - Bethesda
Pennsylvania
- Magee Womens Hospital - Pittsburgh
- UPMC Cancer Center - Pittsburgh
Texas
- MD Anderson Cancer Center - Houston
- Univeristy of Texas Health Science Center in San Antonio - San Antonio
Arizona
- University of Arizona Cancer Center - Tucson
Colorado
- University of Colorado Cancer Center - Aurora
Georgia
- GRU Cancer Center - Georgia Regents University - Augusta
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
What the finished NCT02048059 record still lists
NCT02048059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ANG1005 is the first listed.
NCT02048059 lists 19 locations in 13 states (California, Maryland, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02048059 about?
NCT02048059 is a clinical study titled "ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases". This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
What is the current status of trial NCT02048059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2014-04. Estimated completion is 2017-09.
What conditions does trial NCT02048059 study?
This clinical trial studies the following conditions: Breast Cancer, Brain Metastases.
What interventions are being tested in trial NCT02048059?
The interventions under investigation include: ANG1005 (DRUG).
Who is sponsoring clinical trial NCT02048059?
This trial is sponsored by Angiochem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02048059 being conducted?
This trial has 19 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02048059's enrollment target sits among peer trials
72 685th of 1224 higher than 533 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia